Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

[1] Ploeg M(2009)The present and future burden of urinary bladder cancer in the world World J Urol 27 289-293

[2] Aben KK(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29

[3] Kiemeney LA(2012)Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 J Clin Oncol 30 1107-1113

[4] Siegel R(2006)Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 50-54

[5] Ma J(2000)Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068-3077

[6] Zou Z(2011)International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2171-2177

[7] Jemal A(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-562

[8] Bellmunt J(2013)A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 1212-1218

[9] von der Maase H(2014)Programmed death-1 pathway in cancer and autoimmunity Clin Immunol 153 145-152

[10] Mead GM(2014)Orchestrating immune check-point blockade for cancer immunotherapy in combinations Curr Opin Immunol 27 89-97

[1] Ploeg M(2009)The present and future burden of urinary bladder cancer in the world World J Urol 27 289-293

[2] Aben KK(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29

[3] Kiemeney LA(2012)Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 J Clin Oncol 30 1107-1113

[4] Siegel R(2006)Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 50-54

[5] Ma J(2000)Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068-3077

[6] Zou Z(2011)International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2171-2177

[7] Jemal A(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-562

[8] Bellmunt J(2013)A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 1212-1218

[9] von der Maase H(2014)Programmed death-1 pathway in cancer and autoimmunity Clin Immunol 153 145-152

[10] Mead GM(2014)Orchestrating immune check-point blockade for cancer immunotherapy in combinations Curr Opin Immunol 27 89-97